LBA
SNDX icon

Letko, Brosseau & Associates’s Syndax Pharmaceuticals SNDX Stock Holding History

Letko, Brosseau & Associates’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Buy
+12,450
New +$259K ﹤0.01% 95

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Letko, Brosseau & Associates's SNDX Position: Q2 2026 in Review

Letko, Brosseau & Associates opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 12,450 shares worth $272K. The stake represents ﹤0.01% of the portfolio and ranks #95 among its holdings.

242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Letko, Brosseau & Associates held 12,450 shares of Syndax Pharmaceuticals worth $272K as of Q2 2026.
  • Syndax Pharmaceuticals was a new Letko, Brosseau & Associates position in Q2 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #95 holding.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.